Production (Stage)
OnKure Therapeutics, Inc.
OKUR
$2.88
$0.020.70%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -3.04% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -4.77% | ||||
| Operating Income | 4.77% | ||||
| Income Before Tax | 8.70% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 8.70% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 8.70% | ||||
| EBIT | 4.77% | ||||
| EBITDA | 4.82% | ||||
| EPS Basic | 13.12% | ||||
| Normalized Basic EPS | 8.05% | ||||
| EPS Diluted | 13.12% | ||||
| Normalized Diluted EPS | 8.05% | ||||
| Average Basic Shares Outstanding | 5.09% | ||||
| Average Diluted Shares Outstanding | 5.09% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||